Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-gq7q9 Total loading time: 0 Render date: 2024-07-17T02:22:58.115Z Has data issue: false hasContentIssue false

Chapter 46 - Autologous Hematopoietic Cell Transplants for Plasma Cell Myeloma: One, Two, or None?

from Section 13 - Plasma Cell Dyscrasias: Hematopoietic Cell Transplants

Published online by Cambridge University Press:  24 May 2017

By
Jesus F. San Miguel ,
Juan J. Lahuerta ,
Laura Rosiñol ,
María Victoria Mateos  and
Joan Bladé
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 445 - 457
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blokhin, N, Larionov, L, Perevodchikova, N, Chebotareva, L, Merkulova, N. Clinical experiences with sarcolysin in neoplastic diseases. Ann N Y Acad Sci 1958;68:1128–32.CrossRefGoogle ScholarPubMed
Alexanian, R, Bergsagel, DE, Migliore, PJ, Vaughn, WK, Howe, CD. Melphalan therapy for plasma cell myeloma. Blood 1968;31:1–10.CrossRefGoogle ScholarPubMed
Group, MTC. Combination Chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overwiev of 6.633 patients from 27 randomized studies. J Clin Oncol 1998;16:3832–42.Google Scholar
Larkin, M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet 1999;354:925.CrossRefGoogle ScholarPubMed
Twombly, R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 2003;95:845.CrossRefGoogle ScholarPubMed
Gore, ME, Selby, PJ, Viner, C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2:879–82.Google ScholarPubMed
Alexanian, R, Dimopoulos, M. The treatment of multiple myeloma. N Engl J Med 1994;330:484–9.Google ScholarPubMed
Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001;113:1020–34.Google Scholar
Siegel, DS, Desikan, KR, Mehta, J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51–4.CrossRefGoogle Scholar
Attal, M, Harousseau, JL, Stoppa, AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–7.CrossRefGoogle ScholarPubMed
Barlogie, B, Kyle, RA, Anderson, KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929–36.CrossRefGoogle ScholarPubMed
Blade, J, Rosinol, L, Sureda, A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005;106:3755–9.CrossRefGoogle Scholar
Child, JA, Morgan, GJ, Davies, FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–83.CrossRefGoogle ScholarPubMed
Fermand, JP, Katsahian, S, Divine, M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–33.CrossRefGoogle Scholar
Fermand, JP, Ravaud, P, Chevret, S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131–6.CrossRefGoogle ScholarPubMed
Palumbo, A, Bringhen, S, Petrucci, MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052–7.CrossRefGoogle ScholarPubMed
Segeren, CM, Sonneveld, P, van der Holt, B, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:2144–51.CrossRefGoogle Scholar
Palumbo, A, Triolo, S, Argentino, C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999;94:1248–53.CrossRefGoogle ScholarPubMed
Koreth, J, Cutler, CS, Djulbegovic, B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007;13:183–96.CrossRefGoogle ScholarPubMed
Ludwig, H, Bolejack, V, Crowley, J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010;28:1599–605.CrossRefGoogle ScholarPubMed
Turesson, I, Velez, R, Kristinsson, SY, Landgren, O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28:830–4.CrossRefGoogle ScholarPubMed
Lokhorst, HM, van der Holt, B, Zweegman, S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113–20.CrossRefGoogle ScholarPubMed
Morgan, GJ, Davies, FE, Gregory, WM, et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 2013;19:6030–8.CrossRefGoogle ScholarPubMed
Zervas, K, Mihou, D, Katodritou, E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 2007;18:1369–75.CrossRefGoogle ScholarPubMed
Cavo, M, Tacchetti, P, Patriarca, F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010;376:2075–85.CrossRefGoogle ScholarPubMed
Rosinol, L, Oriol, A, Teruel, AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589–96.CrossRefGoogle ScholarPubMed
Moreau, P, Hulin, C, Macro, M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016;127:2569–74.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Jacobus, S, Callander, NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.CrossRefGoogle ScholarPubMed
Zonder, JA, Crowley, J, Hussein, MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 2010;116:5838–41.CrossRefGoogle Scholar
Sonneveld, P, Goldschmidt, H, Rosinol, L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013;31:3279–87.CrossRefGoogle ScholarPubMed
Popat, R, Oakervee, HE, Hallam, S, et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008;141:512–6.CrossRefGoogle ScholarPubMed
Cavo, M, Pantani, L, Petrucci, MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2013;120:9–19.CrossRefGoogle Scholar
Jakubowiak, AJ, Dytfeld, D, Griffith, KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012;120:1801–9.CrossRefGoogle ScholarPubMed
Sonneveld, P, Asselberg-Hacker, E, Zweegman, S, et al. Dose escalation Phase 2 trial of Carfilzomib combined with thalidomide and low-dose dexamethason In newly diagnosed, transplant eligible patients with multiple myeloma. A trial of the European Myeloma Network. Blood 2013;122:688.CrossRefGoogle Scholar
Kumar, S, Flinn, I, Richardson, PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012;119:4375–82.CrossRefGoogle ScholarPubMed
Reeder, CB, Libby, EN, Costa, LJ, et al. A phase I/II trial of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma: final results of MTD expansion cohort. Blood 2013;122:3179.Google Scholar
Bhutani, D, Zonder, J, Valent, J, et al. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. Support Care Cancer 2013;21:2437–42.CrossRefGoogle ScholarPubMed
Cavo, M, Pantani, L, Pezzi, A. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia 2015;29(12):2429–31.CrossRefGoogle ScholarPubMed
Cavo, M, Salwender, H, Rosiñol, L, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. Blood 2013;122:767.CrossRefGoogle Scholar
Harousseau, JL, Attal, M, Avet-Loiseau, H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28:4621–9.CrossRefGoogle ScholarPubMed
Moreau, P, Facon, T, Attal, M, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731–5.CrossRefGoogle Scholar
Lahuerta, JJ, Mateos, MV, Martinez-Lopez, J, et al. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Haematologica 2010;95:1913–20.CrossRefGoogle ScholarPubMed
Lonial, S, Kaufman, J, Tighiouart, M, et al. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res 2010;16:5079–86.CrossRefGoogle ScholarPubMed
Roussel, M, Moreau, P, Huynh, A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32–7.CrossRefGoogle Scholar
Lazarus, HM, Phillips, GL, Herzig, RH, Hurd, DD, Wolff, SN, Herzig, GP. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol 2008;26:2240–3.CrossRefGoogle ScholarPubMed
Bayraktar, UD, Bashir, Q, Qazilbash, M, Champlin, RE, Ciurea, SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:344–56.CrossRefGoogle ScholarPubMed
Shaw, PJ, C.E. N, Lazarus, HM. Not too little, not too much – just right! (Better ways to give high dose melphalan). Bone Marrow Transplant (in press).Google Scholar
Barlogie, B, Attal, M, Crowley, J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol 2010;28:1209–14.CrossRefGoogle Scholar
Ladetto, M, Pagliano, G, Ferrero, S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010;28:2077–84.CrossRefGoogle ScholarPubMed
Berenson, JR, Crowley, JJ, Grogan, TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002;99:3163–8.CrossRefGoogle ScholarPubMed
Attal, M, Harousseau, JL, Leyvraz, S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289–94.CrossRefGoogle ScholarPubMed
Barlogie, B, Pineda-Roman, M, van Rhee, F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008;112:3115–21.CrossRefGoogle ScholarPubMed
Maiolino, A, Hungria, VT, Garnica, M, et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 2012;87:948–52.CrossRefGoogle ScholarPubMed
Spencer, A, Prince, HM, Roberts, AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788–93.CrossRefGoogle ScholarPubMed
Stewart, AK, Trudel, S, Bahlis, NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 2013;121:1517–23.CrossRefGoogle ScholarPubMed
Kalff, A, Kennedy, N, Smiley, A, et al. Thalidomide consolidation post autologous stem cell transplant (ASCT) for multiple myeloma (MM) is cost-effective with durable survival benefit at 5 years post randomisation: final analysis of the ALLG MM6 Study. Blood 2013;122:537.CrossRefGoogle Scholar
Lokhorst, H, Holt, Bvd, Zweegman, S, et al. Thalidomide combined with high dose melphalan improves event free and overall survival in patients with newly diagnosed multiple myeloma: extended follow-up of the HOVON-50 Trial. Blood 2013;122:3332.CrossRefGoogle Scholar
Hahn-Ast, C, von Lilienfeld-Toal, M, van Heteren, P, Mückter, S, Brossart, P, Glasmacher, A. Improved progression-free and overall survival with thalidomide maintenance therapy after autologous stem cell transplantation in multiple myeloma: a metaanalyis of five randomized trials. Haematologica 2011;96:368.Google Scholar
Hicks, LK, Haynes, AE, Reece, DE, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008;34:442–52.CrossRefGoogle ScholarPubMed
Kagoya, Y, Nannya, Y, Kurokawa, M. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis. Leuk Res 2012;36:1016–21.CrossRefGoogle ScholarPubMed
Ludwig, H, Durie, BG, McCarthy, P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012;119:3003–15.CrossRefGoogle ScholarPubMed
Nooka, AK, Behera, M, Boise, LH, Watson, M, Kaufman, JL, Lonial, S. Thalidomide as maintenance therapy in multiple myeloma (MM) improves progression free survival (PFS) and overall survival (OS): a meta-analysis. ASH Annual Meeting Abstracts 2011;118:1855.Google Scholar
Attal, M, Lauwers-Cances, V, Marit, G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–91.CrossRefGoogle ScholarPubMed
McCarthy, PL, Owzar, K, Hofmeister, CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–81.CrossRefGoogle ScholarPubMed
Palumbo, A, Cavallo, F, Gay, F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895–905.CrossRefGoogle ScholarPubMed
Palumbo, A, Bringhen, S, Kumar, SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014;15:333–42.CrossRefGoogle ScholarPubMed
Sonneveld, P, Schmidt-Wolf, IG, van der Holt, B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012;30:2946–55.CrossRefGoogle ScholarPubMed
Sonneveld, P, Scheid, C, van der Holt, B, et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma:extended follow-up of the HOVON-65/GMMG-HD4 Trial. Blood 2013;122:404.CrossRefGoogle Scholar
Rosinnol, L, Oriol, A, Teruel, AI, et al. Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide versus thalidomide vs. alfa2b-interferon: final results of a phase III Pethema/GEM randomized trial. ASH Annual Meeting Abstracts 2012;120:334.Google Scholar
Barlogie, B, Jagannath, S, Desikan, KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55–65.CrossRefGoogle ScholarPubMed
Naumann-Winter, F, Greb, A, Borchmann, P, Bohlius, J, Engert, A, Schnell, R. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 2012;10:CD004626.Google ScholarPubMed
Attal, M, Harousseau, J-L, Facon, T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495–502.CrossRefGoogle ScholarPubMed
Cavo, M, Tosi, P, Zamagni, E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434–41.CrossRefGoogle ScholarPubMed
Einsele, H, Liebisch, P, Bargou, R, Meisner, C, Metzner, B, Wandt, H. Single high-dose chemoradiotherapy versus tandem high-dose melphalan followed by autologous stem cell transplantation: preliminary analysis [Xth International Myeloma Foundation Workshop, Sydney]. Haematologica 2005;90:131.Google Scholar
Fermand, JP. High does therapy supported with autologous blood stem cell transplantation in multiple myeloma: long term follow-up of the prospective studies of the MAG group [Xth International Myeloma Workshop, Sydney 2005]. Haematologica 2005;90:40.Google Scholar
Goldschmidt, H. Single vs. double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [International Myeloma Workshop, Syndey 2005]. Haematologica 2005;90:38.Google Scholar
Kumar, A, Kharfan-Dabaja, MA, Glasmacher, A, Djulbegovic, B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101:100–6.CrossRefGoogle ScholarPubMed
Giralt, S, Vesole, DH, Somlo, G, et al. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101:964; author reply 6–7.CrossRefGoogle ScholarPubMed
Mehta, J. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101:1430–1; author reply 1–3.CrossRefGoogle ScholarPubMed
Tricot, G, Kern, SE, Barlogie, B. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101:964–6; author reply 6–7.CrossRefGoogle ScholarPubMed
Sonneveld, P, van der Holt, B, Segeren, CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica 2007;92:928–35.CrossRefGoogle ScholarPubMed
Abdelkefi, A, Ladeb, S, Torjman, L, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008;111(4):1805–10.CrossRefGoogle ScholarPubMed
Bruno, B, Rotta, M, Patriarca, F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007;356:1110–20.CrossRefGoogle ScholarPubMed
Gahrton, G, Iacobelli, S, Bjorkstrand, B, et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013;121:5055–63.CrossRefGoogle ScholarPubMed
Garban, F, Attal, M, Michallet, M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474–80.CrossRefGoogle Scholar
Krishnan, A, Pasquini, MC, Logan, B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011;12:1195–203.CrossRefGoogle ScholarPubMed
Lokhorst, HM, van der Holt, B, Cornelissen, JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012;119:6219–25.CrossRefGoogle ScholarPubMed
Rosinol, L, Perez-Simon, JA, Sureda, A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008;112:3591–3.CrossRefGoogle ScholarPubMed
Costa, L, Armeson, K, Hill, E. Tandem autologous transplantation versus autologous plus reduced-intensity conditioning allogeneic transplantation in the management of newly diagnosed multiple myeloma: meta-analysis of all prospective trials with biological randomisation. Bone Marrow Transplant 2013;47:S45.Google Scholar
Kharfan-Dabaja, M, M. H, Reljic, T, Bensinger, W, Djulbegovic, B, Kumar, A. Comparative efficacy of tandem autologous-autologous versus tandem autologous-reduced intensity allogeneic haematopoietic cell transplantation in multiple myeloma: results of a systematic review and meta-analysis. Bone Marrow Transplant 2013;47:S44.Google Scholar
Institute for Quality and Efficiency in Health Care: Executive Summaries. Stem cell transplantation for multiple myeloma: Executive summary of final report: N05-03C, Version 1.0. 2005–2011 Sep19. Epub Date 2014/05/01.Google Scholar
Lokhorst, H, van deHolt, B, Cornelissen, J, et al. No improvement of overall survival after extended follow-up of donor versus no donor analysis of newly diagnosed myeloma patients included in the HOVON 50/54 Study. Blood 2013;122(21):2132–2.CrossRefGoogle Scholar
Crawley, C, Iacobelli, S, Bjorkstrand, B, Apperley, JF, Niederwieser, D, Gahrton, G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–94.CrossRefGoogle ScholarPubMed
Qazilbash, MH, Saliba, R, De Lima, M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084–9.CrossRefGoogle ScholarPubMed
Nishihori, T, Alsina, M. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma. Cancer Control 2011;18:258–67.CrossRefGoogle ScholarPubMed
Rajkumar, SV, Gahrton, G, Bergsagel, PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011;118:3205–11.CrossRefGoogle Scholar
Russell, SJ, Rajkumar, SV. Multiple myeloma and the road to personalised medicine. Lancet Oncol 2011;12:617–9.CrossRefGoogle ScholarPubMed
Siegel, DSd, Jacobus, S, Rajkumar, SV, et al. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in the ECOG E4A03 Randomized Clinical Trial. ASH Annual Meeting Abstracts 2010;116:38.Google Scholar
Cavallo, F, Spencer, A, Gay, F, et al. Early autologous stem cell transplantation improves survival in newly diagnosed multiple myeloma patients. Haematologica 2014;99:520.Google Scholar
Palumbo, A, Gay, F, Spencer, A, et al. A Phase III study of ASCT vs cyclophosphamide-lenalidomide-dexamethasone and lenalidomide-prednisone maintenance vs lenalidomide alone in newly diagnosed myeloma patients. Blood 2013;122:763.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×